An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis

Authors
Category Systematic review
JournalJournal of Neurology, Neurosurgery and Psychiatry
Year 2018
This article has no abstract
Epistemonikos ID: c5128b6b39befd6babe7185209af36474ccb03a1
First added on: Feb 09, 2025